Advanced pancreatic cancer - how to choose an adequate treatment option

Table 1 Phase III trials of combined treatment showing statistically significant survival benefit in metastatic pancreatic cancer

Ref.	Primary endpoint	Treatment arms	No. of patients	OS (mo)
Moore et al[31]	OS	Gemcitabine + erlotinib	569	6.24 vs 5.91
				HR = 0.82
		vs gemcitabine		CI: 0.69-0.99
				P = 0.038
Cunningham et al[22]	OS	Gemcitabine +	533	7.1 vs 6.2
		capecitabine		HR = 0.86
		vs gemcitabine		CI: 0.72-1.02
				P = 0.08
			Meta-analysis
			935	OS NA
				HR = 0.86
				CI: 0.75-0.98
				P = 0.02
Conroy et al[23]	OS	FOLFIRINOX vs gemcitabine	342	11.1 vs 6.8
				HR = 0.57
				CI: 0.45-0.73
				P < 0.0001
Von Hoff et al[25]	OS	Nab-paclitaxel + gemcitabine vs gemcitabine + placebo	861	8.5 vs 6.7
				HR = 0.77
				CI: 0.62-0.83
				P < 0.0001

OS: Overall survival; NA: Not available.